The pharmaceutical industry is constantly exploring methods for process optimization and improvement. Reduction of solvent use and recovery of waste solvents are issues of importance in most API (Active Pharmaceutical Ingredient) manufacturing processes. Process waste streams are often characterized by high volumes of organic solvents that sometimes are difficult to recover and reuse due to azeotopes, resulting in high cost of waste disposal and a large life cycle environmental footprint. Solvent recovery and reuse operations must meet stringent pharmaceutical industry requirements for solvent purity. Rowan University and Pfizer have collaborated to explore green engineering alternatives for waste minimizing solvent recovery processes for the Celecoxib process. A case study has been performed that explores pollution prevention and remission opportunities for the current process. Two viable techniques, pervaporation-distillation hybrids and extractive distillation, have been identified to treat the process waste. The case study describes equipment and processing issues, financial costs and benefits; and environmental impacts through life cycle assessment techniques.